BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study.

doi:10.1016/j.lungcan.2016.02.011

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study.

Lung cancer (Amsterdam, Netherlands) - 1 May 2016

Vavalà Tiziana, Follador Alessandro, Tiseo Marcello, Galetta Domenico, Morabito Alessandro, Di Maio Massimo, Martelli Olga, Caffo Orazio, Piovano Pier Luigi, Cortinovis Diego, Zilembo Nicoletta, Casartelli Clelia, Banna Giuseppe Luigi, Ardizzoia Antonio, Barzelloni Maria Luisa, Bearz Alessandra, Genestreti Giovenzio, Mucciarini Claudia, Filipazzi Virginio, Menis Jessica, Rizzo Elisa, Barbieri Fausto, Rijavec Erika, Cecere Fabiana, Bria Emilio, Spitaleri Gianluca, Rossi Antonio, Novello Silvia

Abstract excerpt

OBJECTIVES: Non-small-cell-lung-cancer (NSCLC) patients harbouring epidermal growth factor receptor (EGFR) mutations develop drug resistance after 9-12 months of EGFR tyrosine kinase inhibitors (TKIs) therapy pointing out the issue of the second-line treatment choice. MATERIALS AND METHODS: From June 2009 until May 2013 patients affected by advanced NSCLC harbouring EGFR mutations receiving first-line TKI were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Italy

Share to Neoplasm Metastasis

Share to Neoplasm Staging

Share to Protein Kinase Inhibitors

Share to Retreatment

Source

Open in PubMed

Identifiers

PMID: 27040855
DOI: 10.1016/j.lungcan.2016.02.011

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study.PMID 27040855Read ↗

Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study.Semantic proximity Read ↗

Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.Semantic proximity Read ↗

Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.Semantic proximity Read ↗

Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study.Semantic proximity Read ↗

EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational StudySemantic proximity Read ↗

Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study.Semantic proximity Read ↗

Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study.Semantic proximity Read ↗

Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI's: Exploration of efficacy of unselected treatment in a multicenter cohort study.Semantic proximity Read ↗

Beyond EGFR TKI in EGFR-mutant non-small cell lung cancer patients: main challenges still to be overcome.Semantic proximity Read ↗

A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First or Second Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer: The ‘LUNGFUL’ StudySemantic proximity Read ↗

Prospective cohort study of clinical characteristics and management patterns for patients with non-small-cell lung cancer in the Russian Federation: EPICLIN-Lung.Semantic proximity Read ↗

Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.